Comparison · NCT04840199-sae
Letermovir vs No Anti-CMV Treatment: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Letermovir vs No Anti-CMV Treatment: serious adverse events. Trial comparisons, record NCT04840199-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04840199-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0526 | 0.00935 | 0.246 | wilson | |
| Risk in group 2 | 0.0455 | 0.00807 | 0.218 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00718 | -0.171 | 0.205 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.16 | 0.0776 | 17.3 | log | |
| Odds ratio, group 1 over group 2 | 1.17 | 0.068 | 20 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Letermovir than on No Anti-CMV Treatment | 139 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Letermovir | Participants randomized to letermovir for 48 weeks followed by 12 weeks off letermovir~Letermovir Oral Tablet: 480 mg administered orally once daily with or without food | 1 | 19 | EG000 |
| Group 2 | No Anti-CMV Treatment | Participants randomized to no study intervention for 60 weeks | 1 | 22 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- From study entry to Week 60, or premature study discontinuation
Source ClinicalTrials.gov
Trial
- Title
A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes.
- NCT number
- NCT04840199
- Phases
- PHASE2
- Conditions
- HIV Infections, Cytomegalovirus, CMV
- Interventions
- Letermovir Oral Tablet
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Results first posted
- 2025-03-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04840199?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04840199-sae